News
After CagriSema blow, Novo reveals data for obesity 'triple'
Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.
Saturday 28 February 2026
